22 patients with advanced non-small-cell lung cancer were randomized to receive chemotherapy (ifosfamide) or chemotherapy followed by thymosin α1 + low-dose IFNα. Chemo-immunotherapy induced an enhanced response rate compared with chemotherapy alone (33% and 10% respectively). Although these differences were not significant, the difference in time to progression was (p = 0.0059). CD4+, CD8+ and NK cell counts were significantly depressed after two cycles of chemotherapy, while no difference in cell count were seen in chemo-immunotherapy treated patients. Hematologic toxicity was reduced by the immunotherapy, with no grade 3/4 toxicity seen compared to 50% in patients treated with chemotherapy alone.
Salvati F., R.G. (1996). Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: A Phase-II controlled trial. ANTICANCER RESEARCH, 16(2), 1001-1004.
Tipologia: | Articolo su rivista | |
Citazione: | Salvati F., R.G. (1996). Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: A Phase-II controlled trial. ANTICANCER RESEARCH, 16(2), 1001-1004. | |
IF: | Con Impact Factor ISI | |
Lingua: | English | |
Settore Scientifico Disciplinare: | Settore MED/07 - Microbiologia e Microbiologia Clinica | |
Revisione (peer review): | Sì, ma tipo non specificato | |
Tipo: | Articolo | |
Rilevanza: | Rilevanza internazionale | |
Stato di pubblicazione: | Pubblicato | |
Data di pubblicazione: | 1996 | |
Titolo: | Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: A Phase-II controlled trial | |
Autori: | ||
Autori: | Salvati F., Rasi G., Portalone L., Antilli A., Garaci E. | |
Appare nelle tipologie: | 01 - Articolo su rivista |